Li-Chuan Chan

7.8k total citations · 3 hit papers
27 papers, 2.1k citations indexed

About

Li-Chuan Chan is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Li-Chuan Chan has authored 27 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Li-Chuan Chan's work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (7 papers) and PARP inhibition in cancer therapy (5 papers). Li-Chuan Chan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (7 papers) and PARP inhibition in cancer therapy (5 papers). Li-Chuan Chan collaborates with scholars based in Taiwan, United States and China. Li-Chuan Chan's co-authors include Mien‐Chie Hung, Jong‐Ho Cha, Jennifer L. Hsu, Chia‐Wei Li, Jung-Mao Hsu, Jennifer L. Hsu, Seung-Oe Lim, Chia-Wei Li, Weiya Xia and Kay‐Hooi Khoo and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Molecular Cell.

In The Last Decade

Li-Chuan Chan

27 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms Controlling PD-L1 Expression in Cancer

2019 710 citations Jong‐Ho Cha, Li-Chuan Chan et al. Molecular Cell profile →
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

2018 354 citations Jung-Mao Hsu, Weiya Xia et al. Nature Communications profile →
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

2021 255 citations Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Li-Chuan Chan Taiwan	17	1.2k	965	779	425	406	27	2.1k
Xinhui Wang United States	21	917 0.8×	828 0.9×	536 0.7×	251 0.6×	459 1.1×	55	1.9k
Maarten Slagter Netherlands	7	1.4k 1.2×	598 0.6×	937 1.2×	411 1.0×	373 0.9×	9	2.0k
Limo Chen United States	18	1.0k 0.9×	816 0.8×	712 0.9×	276 0.6×	257 0.6×	26	1.9k
Jaclyn Sceneay Australia	18	1.4k 1.2×	1.2k 1.3×	1.0k 1.3×	607 1.4×	756 1.9×	21	2.7k
Dominique C. Hinshaw United States	8	989 0.9×	1.2k 1.2×	887 1.1×	669 1.6×	708 1.7×	23	2.4k
Joe Stephenson United States	25	1.1k 0.9×	894 0.9×	429 0.6×	488 1.1×	360 0.9×	65	2.0k
Anna E. Vilgelm United States	23	1.0k 0.9×	773 0.8×	630 0.8×	283 0.7×	196 0.5×	48	1.9k
Annemilaï Tijeras‐Raballand France	21	1.2k 1.0×	1.2k 1.2×	540 0.7×	264 0.6×	503 1.2×	47	2.2k
Pedro P. López‐Casas Spain	25	978 0.8×	702 0.7×	317 0.4×	340 0.8×	540 1.3×	52	1.8k
Won Jin Ho United States	18	1.3k 1.2×	612 0.6×	629 0.8×	340 0.8×	438 1.1×	59	2.1k

Countries citing papers authored by Li-Chuan Chan

Since Specialization

Citations

This map shows the geographic impact of Li-Chuan Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li-Chuan Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li-Chuan Chan more than expected).

Fields of papers citing papers by Li-Chuan Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li-Chuan Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li-Chuan Chan. The network helps show where Li-Chuan Chan may publish in the future.

Co-authorship network of co-authors of Li-Chuan Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Li-Chuan Chan. A scholar is included among the top collaborators of Li-Chuan Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li-Chuan Chan. Li-Chuan Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Markosyan, Nune, Il‐Kyu Kim, Nikhil Joshi, et al.. (2024). Pivotal roles for cancer cell–intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity. JCI Insight. 9(21). 3 indexed citations

Sun, Xian Wen, Wei‐Jan Wang, Ri‐Yao Yang, et al.. (2023). Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. International Journal of Biological Sciences. 19(14). 4644–4656. 8 indexed citations

Wang, Ying‐Nai, Heng‐Huan Lee, Zhou Jiang, et al.. (2023). Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. International Journal of Biological Sciences. 19(10). 2957–2973. 9 indexed citations

Zhao, Xixi, Yongkun Wei, Yu‐Yi Chu, et al.. (2022). Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Research. 82(11). 2185–2195. 36 indexed citations

Jiang, Zhou, Seung-Oe Lim, Meisi Yan, et al.. (2021). TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation. 131(8). 255 indexed citations breakdown →

Nie, Lei, Junwei Hou, Yu‐Yi Chu, et al.. (2021). Abstract 120: Compartmentalized functions of epidermal growth factor receptor (EGFR) in tumorigenesis and malignant phenotypes. Cancer Research. 81(13_Supplement). 120–120. 2 indexed citations

Sun, Linlin, Chia-Wei Li, Ezra M. Chung, et al.. (2020). Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research. 80(11). 2298–2310. 133 indexed citations

Chu, Yu‐Yi, Clinton Yam, Mei‐Kuang Chen, et al.. (2020). Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.. PubMed. 10(2). 648–661. 36 indexed citations

Wang, Yuhan, Linlin Sun, Ri‐Yao Yang, et al.. (2020). Abstract 6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity. Cancer Research. 80(16_Supplement). 6527–6527. 2 indexed citations

10.

Liu, Chunxiao, Zhengyu Zha, Chenhao Zhou, et al.. (2020). Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology. 74(4). 907–918. 21 indexed citations

11.

Cha, Jong‐Ho, Li-Chuan Chan, Min Sup Song, & Mien‐Chie Hung. (2019). New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine. 10(8). a036863–a036863. 90 indexed citations

12.

Cha, Jong‐Ho, Li-Chuan Chan, Chia‐Wei Li, Jennifer L. Hsu, & Mien‐Chie Hung. (2019). Mechanisms Controlling PD-L1 Expression in Cancer. Molecular Cell. 76(3). 359–370. 710 indexed citations breakdown →

13.

Han, Ye, Chia-Wei Li, Jung-Mao Hsu, et al.. (2019). Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.. PubMed. 9(4). 800–815. 37 indexed citations

14.

Hsu, Jung-Mao, Weiya Xia, Yi‐Hsin Elsa Hsu, et al.. (2018). STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature Communications. 9(1). 1908–1908. 354 indexed citations breakdown →

15.

Yang, Wenhao, Jong‐Ho Cha, Weiya Xia, et al.. (2018). Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Research. 78(14). 3761–3768. 21 indexed citations

16.

Shao, Bin, Chia-Wei Li, Seung‐Oe Lim, et al.. (2018). Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.. PubMed. 8(9). 1837–1846. 60 indexed citations

17.

Ko, How-Wen, Heng‐Huan Lee, Longfei Huo, et al.. (2016). GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 7(35). 57131–57144. 34 indexed citations

18.

Chan, Li-Chuan, et al.. (2014). In vivo growth suppression of CT-26 mouse colorectal cancer cells by adenovirus-expressed small hairpin RNA specifically targeting thymosin beta-4 mRNA. Cancer Gene Therapy. 21(9). 389–396. 7 indexed citations

19.

Chan, Li-Chuan, Yi‐Chen Yeh, Cheng‐Yu Chen, et al.. (2011). Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. Cancer Letters. 308(2). 162–171. 44 indexed citations

20.

Chan, Li-Chuan, et al.. (2006). Use of a recombinant protein containing major epitopes of hnRNP G to detect anti-hnRNP G antibodies in dogs with systemic lupus erythematosus. Research in Veterinary Science. 81(3). 335–339. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact